The most established molecular biomarker for predicting the outcome of GBM is methylation of the O6-methylguanine-DNA methyltransferase (MGMT) promoter, associated with a positive response to temozolomide, which is used in first-line treatment in combination with radiotherapy [4,5]. The gene discussed is MGMT; the disease is glioblastoma.